Table 1

Characteristics of Acinetobacter nosocomialis isolatesa

Type of sampleIsolateSpecimen sourceIsolation date (day/mo/yr)Allelic profile (UO scheme)ST (UO/IP)Resistance profile
Human clinical specimenAn2bTracheal secretion16/5/200711-65-14-21-37-105-15260/161CAZ, CIP, GEN, SXT, TOB
An2aTracheal secretion6/7/200711-67-14-51-37-105-15NA(260DLV)/161CIP, GEN, SXT, TOB
An8Blood13/7/200711-65-14-21-37-105-15260/161AMI, CIP, FEP, GEN, TOB
An7bTracheal secretion26/7/200711-65-14-21-37-105-15260/161CIP, GEN, SXT, TOB
ICUCTI021ICU cabinet28/5/200811-70-14-21-37-4-15264(260DLV)None
CTI10Ventilator equipment28/5/200811-27-ND-21-37-113-15NDSXT
CTI15.3Hand of ICU staff28/5/200811-65-93- 61-25-112-15263FEP, SXT, TZP
Environment unrelated to hospitalPCA073Water reservoir13/12/200749- 68-119-53-41-115-58262TOB
PCA111Water reservoir14/3/200842-36-92-30-40-114-57261None
A12.1Lettuce25/3/200811-65-14-21-37-105-15260/161CIP
  • a ICU, intensive care unit; UO, University of Oxford MLST scheme; ND, not determined; ST, sequence type; IP, Institut Pasteur; NA, not assigned; DLV, double-locus variant; AMI, amikacin; CIP, ciprofloxacin; FEP, cefepime; GEN, gentamicin; TOB, tobramycin; CAZ, ceftazidime; SXT, sulfamethoxazole-trimethoprim; TZP, piperacillin-tazobactam.